Bios­plice search­es for a path for­ward af­ter os­teoarthri­tis drug fails late-stage study

Bios­plice’s os­teoarthri­tis drug has failed a Phase 3 clin­i­cal tri­al, ac­cord­ing to the drug­mak­er, sig­nif­i­cant­ly cloud­ing the drug’s chances of ap­proval and the fu­ture of a com­pa­ny that was once val­ued at $12 bil­lion.

The small-mol­e­cule drug, lore­ci­vivint, has pre­vi­ous­ly gen­er­at­ed mixed da­ta in a hand­ful of late-stage stud­ies. And de­spite the tri­al fail­ure, Bios­plice told End­points News that it doesn’t plan to con­duct ad­di­tion­al tri­als, will dis­cuss the da­ta with the FDA, and is bet­ting the com­pound has a path for­ward.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER